Quantcast

Latest International AIDS Vaccine Initiative Stories

2010-07-20 06:49:00

VIENNA, July 20 /PRNewswire-USNewswire/ -- Following significant advances in vaccine and microbicide research, including results presented today of 39% efficacy in the CAPRISA 004 microbicide gel trial among women in South Africa, a new report released today warns that flat funding for HIV prevention research may limit researchers' ability to quickly move promising approaches forward. The report examines investment in HIV prevention research in 2009 and finds that the onset of a global...

2010-07-19 06:00:00

In Keynote Speech to AIDS Conference, Gates Outlines Roadmap to Reduce Annual New HIV Infections 90% by 2031 VIENNA, July 19 /PRNewswire-USNewswire/ -- Speaking to the 18th International AIDS Conference today, Bill Gates called on all countries to keep up the fight against HIV/AIDS, saying the world has an historic opportunity to "change the face of AIDS." Mr. Gates said current efforts to treat people with HIV are saving millions of lives, and urged a renewed focus on reducing annual...

2010-07-02 13:47:00

SMYRNA, Ga., July 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is mentioned in two recent articles covering a historic HIV vaccine trial currently being conducted by the AIDS Research Consortium of Atlanta (ARCA) using a vaccine supplied by GeoVax. The first article, titled "ARCA Seeks Volunteers For Historic HIV Vaccine Trial," appeared in the June 11 print and online...

2010-06-02 13:43:02

The findings advance the effort to develop an AIDS vaccine In findings that contribute to efforts to design an AIDS vaccine, a team led by Scripps Research Institute scientists has determined the structure of an immune system antibody molecule that effectively acts against most strains of human immunodeficiency virus (HIV), the virus that causes AIDS. The study, which is being published in an advance, online issue of the journal Proceedings of the National Academy of Sciences (PNAS) during...

2010-05-27 11:07:00

ATLANTA, May 27 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, announced today The AIDS Research Consortium of Atlanta (ARCA) has received approval to begin enrollment of the first therapeutic trial ever conducted using a promising HIV vaccine candidate from GeoVax, Inc. Although the GeoVax vaccines are currently being studied for HIV prevention, this is the first study using the...

2010-05-20 07:00:00

SMYRNA, Ga., May 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, is spotlighted on an interactive map posted on the website of Inc. magazine. The map, created by Nitasha Tiku and April Joyner, is headlined "Incubation Nation: Where Great Ideas Are Born." Tiku and Joyner write: "Spun out of university research labs or started by local entrepreneurs trying to supercharge...

2010-05-17 12:23:00

NEW YORK, May 17 /PRNewswire-USNewswire/ -- For more than a decade, researchers and advocates have marked HIV Vaccine Awareness Day with varying degrees of hope, cynicism and despair. This year, in large part because of the results of the Thai Prime-Boost vaccine study, there is greater cause for hope than ever before and a renewed sense of urgency to transform this hope into a reality. In September 2009, the world's largest AIDS vaccine trial to date showed the first evidence that an...

2010-05-17 09:58:00

SMYRNA, Ga., May 17 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops and tests innovative HIV/AIDS vaccines, today announced that its Chief Scientific Officer, Harriet L. Robinson, Ph.D., will speak at a symposium devoted to the development of HIV/AIDS vaccines to be held at the New York Academy of Sciences in New York City on Wednesday, May 19. The one-day symposium, titled "HIV/AIDS: Vaccines and alternate strategies...

2010-04-29 11:10:00

ATLANTA, April 29 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVXD), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, is participating in the BIO International Convention (BIO2010) taking place May 3-6, 2010 in Chicago, IL at McCormick Place. This event, hosted by the Biotechnology Industry Organization (BIO), will feature high-level industry leaders discussing public policy issues of critical importance to all segments of the...

2010-04-27 16:00:00

ATLANTA, April 27 /PRNewswire/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), a biotechnology company that creates, develops, and tests innovative HIV/AIDS vaccines, has issued a letter to its shareholders and has added a question and answer section to its website. To view the shareholder letter in its entirety, please follow this link to the Company's website: www.geovax.com. In the letter, GeoVax Labs President and CEO Robert T. McNally, PhD, updates shareholders on the Company's...


Word of the Day
glogg
  • Scandinavian punch made of claret and aquavit with spices and raisins and orange peel and sugar.
This word comes from the Swedish 'glogg,' which is an alteration of 'glodgat,' mulled (wine).
Related